Next Generation Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area (Oncology, Autoimmune/ Inflammatory Diseases), By Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments, Antibody-like Proteins, Others), By Region & Competition, 2020-2030F

Market Overview

The Next Generation Biotherapeutics market was valued at USD 5.42 Billion in 2024 and is expected to reach USD 10.75 Billion by 2030 with a CAGR of 12.05%. Next Generation Biotherapeutics, also known as NGBTs, represent a significant and groundbreaking advancement in the field of medicine. These innovative therapies focus on the development of novel biological treatments for a wide range of diseases. By harnessing the power of cutting-edge technologies such as gene therapy, cell therapy, RNA interference, and the use of monoclonal antibodies, NGBTs offer a highly targeted approach to treatment. These therapies are designed to specifically target disease pathways with unrivaled precision, minimizing side effects and maximizing therapeutic efficacy. By doing so, they hold the potential to revolutionize the way we approach medical treatment. With their ability to deliver personalized and tailored healthcare solutions, NGBTs are paving the way for a new era in biomedical innovation. The impact of NGBTs extends far beyond traditional treatment protocols. They not only offer hope to patients who have exhausted conventional treatments, but they also open doors to new possibilities in healthcare. By unlocking the potential of the human body's own mechanisms and utilizing advanced technologies, NGBTs have the potential to transform the landscape of medicine, providing patients with better outcomes and improved quality of life. As research and development in this field continue to progress, the future of Next Generation Biotherapeutics holds great promise. With each new discovery, we inch closer to uncovering breakthrough treatments for currently incurable diseases. The continued advancement of NGBTs represents a beacon of hope for patients and healthcare professionals alike, offering a glimpse into a future where diseases can be effectively managed, if not eradicated.

Key Market Drivers

Increasing Incidence of Cancer

The increasing incidence of cancer is undeniably a significant driver behind the escalating demand for Next Generation Biotherapeutics (NGB). The global cancer burden is expected to escalate sharply, with incidence projected to surge by 77% by 2050 relative to 2022 levels. Cancer remains a global health challenge, and NGB offers innovative and targeted treatment solutions. Cancer is a highly heterogeneous disease with diverse genetic mutations driving its development. NGB leverages advanced genomic profiling to identify these genetic alterations in individual patients. This personalized approach allows for the development of biotherapeutics tailored to the specific genetic makeup of each patient, optimizing treatment efficacy.

As cancer cells can develop resistance to traditional chemotherapy and radiation therapy, the demand for alternative treatment options is growing. NGB provides a promising avenue to overcome treatment resistance by targeting the underlying genetic drivers of cancer. NGB allows for the precise targeting of cancer cells while sparing healthy tissues, minimizing adverse effects associated with conventional treatments. This high degree of specificity enhances patient quality of life during treatment.

Ongoing research utilizing NGB technologies is uncovering new therapeutic targets and pathways in cancer biology. These discoveries lead to the development of novel biotherapeutics, including monoclonal antibodies, CAR-T cell therapies, and mRNA-based vaccines. NGB is instrumental in advancing cancer immunotherapies, such as immune checkpoint inhibitors and personalized cancer vaccines. These treatments harness the patient's immune system to combat cancer, and NGB helps identify suitable immunotherapy candidates based on their unique genetic profiles. The increasing incidence of cancer is driving a growing demand for Next Generation Biotherapeutics. As NGB technologies continue to advance, they offer a beacon of hope for patients, providing tailored and effective treatments that aim to improve outcomes and quality of life for those affected by this devastating disease.

Rising Prevalence of Autoimmune Diseases

The rising prevalence of autoimmune diseases is a major catalyst behind the increasing demand for Next Generation Biotherapeutics (NGB). Autoimmune diseases, characterized by the immune system mistakenly attacking the body's own tissues, affect millions of people globally. Chronic autoimmune and inflammatory disorders are showing a marked upward trend, with significant implications for healthcare markets. In the U.S., celiac disease prevalence has risen five-fold over the past three decades, effectively doubling every 15 years underscoring a growing patient base for gluten-free therapeutics and diagnostics. Globally, multiple sclerosis cases rose by 30% between 2013 and 2022, highlighting increased demand for long-term neurological care and disease-modifying therapies. Meanwhile, the prevalence of inflammatory bowel disease (IBD) surged by 46% from 2006 to 2021, signaling expanding market potential for advanced biologics, precision treatments, and GI-focused care solutions.

Autoimmune diseases are highly complex and heterogeneous, often involving a multitude of immune dysregulations. NGB enables precise targeting of specific immune pathways and molecules responsible for these diseases, offering a more tailored and effective therapeutic approach.  NGB technologies facilitate the discovery of biomarkers associated with autoimmune diseases. These biomarkers help identify individuals at risk, enable early diagnosis, and guide treatment decisions, increasing the demand for NGB-based diagnostics and therapies. The unique genetic and immune profiles of individuals with autoimmune diseases make personalized medicine a crucial approach. NGB allows for the customization of biotherapeutics based on a patient's genetic and immunological characteristics, optimizing treatment outcomes.

NGB contributes to the advancement of biologics, such as monoclonal antibodies and fusion proteins, that specifically target immune cells and molecules involved in autoimmune diseases. These innovative treatments offer improved efficacy and reduced side effects. The rising prevalence of autoimmune diseases is a significant driver of the demand for Next Generation Biotherapeutics. As research and development efforts in this field continue to expand, NGB holds the promise of providing more effective, personalized, and targeted treatments for individuals affected by autoimmune conditions, ultimately improving their quality of life and clinical outcomes.

Increasing R&D Activities using NGS technologies

The burgeoning field of Next Generation Biotherapeutics (NGB) is experiencing a surge in demand, thanks to the increasing research and development (R&D) activities utilizing Next-Generation Sequencing (NGS) technologies. NGB represents a promising frontier in medicine, offering highly personalized and targeted treatments by harnessing genetic information. NGS technologies allow for comprehensive genomic profiling, enabling the identification of genetic variations and mutations associated with diseases. This precise understanding of a patient's genetic makeup is the foundation of NGB, allowing for the development of tailored therapies.

R&D efforts employing NGS techniques facilitate the discovery of novel therapeutic targets at a genetic level. This leads to the development of innovative biotherapeutics designed to specifically target the underlying genetic causes of diseases. NGS generates vast amounts of genetic data, which can be harnessed for research and development purposes. This wealth of information aids in the design of more effective biotherapeutics, contributing to the demand for NGB. NGS technologies open new avenues for tackling rare and previously undruggable diseases. Researchers can identify genetic mutations responsible for such conditions and develop biotherapeutics that address these specific genetic defects.

The speed and efficiency of NGS-driven R&D enable faster drug development and clinical trials. This acceleration is vital, particularly for patients with life-threatening conditions who require rapid access to innovative therapies. NGS plays a critical role in pharmacogenomics, which focuses on tailoring drug treatments to an individual's genetic profile. This personalized approach enhances treatment outcomes and minimizes adverse effects.

Technological Progressions in Biotherapeutics

Technological progressions in the field of biotherapeutics are playing a pivotal role in increasing the demand for Next Generation Biotherapeutics (NGB). These advancements encompass a range of innovative approaches and techniques that are reshaping the landscape of biotherapeutic development and application. Cutting-edge technologies enable the design and development of biotherapies that specifically target disease-causing molecules or cells. This precision minimizes off-target effects and maximizes therapeutic efficacy, making NGB highly sought after.

Advancements in monoclonal antibody engineering and manufacturing have led to the creation of more potent and versatile therapeutics. These antibodies are central to NGB, as they can be customized to target a wide range of diseases, from cancer to autoimmune disorders. Technological progress in gene editing and gene delivery systems has paved the way for gene therapies within the realm of NGB. These therapies offer the potential to correct genetic abnormalities, treat rare diseases, and provide personalized treatments. Chimeric Antigen Receptor T-cell (CAR-T) therapies, a form of cellular immunotherapy, are at the forefront of NGB. Technological advancements in CAR-T cell engineering enhance their specificity, persistence, and safety in treating various cancers. Technological progressions in biotherapeutics are fueling the demand for Next Generation Biotherapeutics across a spectrum of diseases. These advancements empower researchers and clinicians to develop more effective, precise, and personalized treatments, revolutionizing the field of medicine and providing hope for patients facing a wide array of health challenges. As these technologies continue to evolve, their impact on healthcare is poised to grow, further elevating the demand for NGB.

Download Free Sample Report

Key Market Challenges

Stringent Regulatory Framework

While Next Generation Biotherapeutics (NGB) hold immense promise in revolutionizing healthcare, stringent regulatory frameworks can pose challenges that may decrease their demand. These regulations, while crucial for ensuring the safety and efficacy of biotherapies, can slow down their development, increase costs, and limit accessibility. Stringent regulatory requirements often result in lengthy development timelines for NGB. Extensive preclinical and clinical testing, as well as rigorous safety evaluations, can delay the availability of innovative biotherapies, hindering their timely delivery to patients in need.

The stringent regulatory demands translate into higher development costs for NGB. Companies and research institutions must invest significant resources in meeting regulatory standards, potentially limiting the number of entities willing to engage in the development of these therapies. Complex regulatory pathways can serve as barriers to entry for smaller biotechnology companies and startups. This can limit competition and innovation in the field, potentially reducing the diversity of available NGB treatments. Delays caused by stringent regulations can limit patient access to NGB, particularly in cases where these therapies represent the best or only available treatment option. Patients facing life-threatening conditions may not have the luxury of waiting for lengthy approval processes.

High costs of Next-Generation Biotherapeutics

The high costs associated with Next Generation Biotherapeutics (NGB) are a significant factor that can decrease their demand and limit accessibility. While NGB hold great promise for revolutionizing healthcare and offering personalized treatments, the financial burden they impose on healthcare systems, patients, and payers can pose substantial challenges. The exorbitant costs of NGB can render these therapies financially inaccessible to many patients, particularly those without comprehensive insurance coverage. The prospect of facing substantial out-of-pocket expenses can deter individuals from seeking or adhering to NGB treatments. The high price tags associated with NGB can strain healthcare system budgets, especially in publicly funded healthcare systems. Limited resources may force healthcare providers and governments to make difficult decisions about which treatments to offer, potentially excluding NGB from coverage.

The high costs of Next Generation Biotherapeutics can indeed reduce their demand and hinder their broader adoption. Striking a balance between the need for innovation and affordability is crucial to ensure that these groundbreaking therapies are accessible to those who can benefit from them. Collaborative efforts among stakeholders, including healthcare providers, insurers, pharmaceutical companies, and policymakers, are essential to address the cost challenges associated with NGB and make them more widely accessible.

Key Market Trends

Increasing Aging Population

The increasing aging population is a significant driver behind the growing demand for Next Generation Biotherapeutics (NGB). The global demographic landscape is shifting rapidly, with the share of the population aged 65 and older expected to rise from 10% in 2021 to 16% by 2050, and further to 24% by 2100. As the world's population ages, the prevalence of age-related and chronic diseases rises substantially. NGB, with its potential to offer precise and innovative treatment options, plays a critical role in addressing the complex healthcare needs of this demographic. With aging comes a higher susceptibility to various age-related diseases such as cancer, neurodegenerative disorders, cardiovascular diseases, and osteoarthritis. NGB offers targeted therapies that can address the underlying genetic and molecular factors driving these conditions, increasing their appeal for the aging population. Older individuals often contend with multiple chronic conditions simultaneously. NGB's capacity for personalized, multifaceted treatments is well-suited to manage these complex medical profiles, providing a more holistic approach to care.

NGB is at the forefront of personalized medicine, tailoring treatments to an individual's unique genetic and molecular profile. This approach is particularly relevant for older adults, who may have distinct medical histories and genetic factors influencing their health. By effectively treating age-related diseases and reducing hospitalizations, NGB has the potential to lower healthcare costs associated with the aging population, making it an attractive option for healthcare systems and payers.

Advances in Biotechnology and Biomedical Engineering

Advances in biotechnology and biomedical engineering have ushered in a new era of healthcare, with a profound impact on the development and demand for next-generation biotherapeutics. These innovations have revolutionized our understanding of diseases and their underlying mechanisms, allowing for the creation of highly targeted and personalized treatments. As a result, the demand for next-generation biotherapeutics, including gene therapies, monoclonal antibodies, and cell-based therapies, has surged.

Advances in Biotechnology and Biomedical Engineering are driving an increased demand for Next Generation Biotherapeutics. These advancements have led to a pioneering shift, enabling scientists to develop therapeutic solutions tailored to individual genetic profiles. Leveraging the insights from genomics and proteomics, researchers are now able to devise targeted treatments for various ailments, significantly improving the efficacy and reducing adverse effects. This personalized approach to medicine is revolutionizing the healthcare industry by providing treatments that are optimized for each patient's unique biological makeup, leading to better clinical outcomes and enhanced patient satisfaction. Furthermore, innovations in drug delivery systems, enabled by advancements in nanotechnology, are creating opportunities for non-invasive and controlled release of these biotherapeutics, further augmenting their demand. The increasing prevalence of chronic diseases and the need for effective treatments have also fueled this surge in demand.

Segmental Insights

Therapeutic Area Insights

Based on the therapeutic area, the oncology segment emerged as the fastest growing segment in the Global Next Generation Biotherapeutics Market. Traditional treatment modalities such as chemotherapy and radiation often yield limited outcomes and substantial side effects. This has accelerated demand for next-generation biotherapeutics including cell therapies, gene therapies, antibody-drug conjugates (ADCs), and immune checkpoint inhibitors that offer higher specificity, improved efficacy, and reduced toxicity.

Oncology dominates the global biotherapeutic development pipeline. Over 40% of next-gen biologics in clinical development target various forms of cancer. The segment benefits from faster regulatory approvals under priority review, breakthrough therapy, and accelerated pathways, allowing quicker time-to-market and early revenue realization. This has made oncology an attractive focus for biotech startups and established pharmaceutical players alike. Due to the high clinical urgency and potential to improve survival outcomes, next-gen oncology therapies often receive premium pricing and favorable reimbursement policies. Governments and payers in key markets such as the U.S., EU, and Japan are increasingly supporting high-cost oncology therapies when backed by strong clinical evidence, improving commercial viability.

Download Free Sample Report

Regional Insights

North America emerged as the largest market in the Global Next Generation Biotherapeutics Market. North America, particularly the U.S., leads globally in biopharmaceutical innovation. The region is home to a dense concentration of biotech startups, academic research institutions, and multinational pharma companies that are actively investing in next-generation platforms such as gene therapies, cell therapies, RNA-based drugs, and antibody-drug conjugates (ADCs). This innovation ecosystem is supported by access to venture capital, government grants (e.g., NIH funding), and strategic collaborations with academic labs and contract research organizations (CROs).

The U.S. Food and Drug Administration (FDA) plays a pivotal role in fostering market growth through progressive regulatory frameworks. Programs like Breakthrough Therapy Designation, Fast Track, and Accelerated Approval have significantly reduced the time-to-market for novel biotherapeutics. These mechanisms provide a favorable environment for companies to bring next-generation products to patients faster, boosting early commercialization and market capture. North American healthcare providers and payers exhibit a high level of readiness to adopt innovative treatments, especially in areas with unmet clinical needs. Physicians are more likely to prescribe advanced biologics when supported by strong clinical data, and patients have better access due to broader insurance coverage and specialty pharmacy networks. This has led to faster uptake of new therapies, particularly in oncology and rare genetic disorders.

Recent Developments   

• In April 2025, NBE Therapeutics, a Swiss biotech acquired by Boehringer Ingelheim in 2020, has become a cornerstone of the company’s oncology R&D strategy. The newly established facility is set to function as a flagship research hub dedicated to advancing antibody-drug conjugate (ADC) technologies, reinforcing Boehringer’s commitment to developing next-generation cancer therapies with the potential to deliver transformative clinical outcomes.
• In January 2025, Silexion Therapeutics is solidifying its foothold in the precision oncology space, following promising preclinical results demonstrating the efficacy of systemically administered SIL-204 in targeting KRAS-driven cancers. This advancement not only reinforces the therapeutic potential of SIL-204 but strategically positions Silexion as a high-value player amid a surge in industry demand for differentiated oncology assets—reflected in a wave of recent multi-billion-dollar acquisitions across the sector.
• In December 2024, UK-headquartered pharmaceutical leader AstraZeneca has unveiled a strategic realignment of its biopharma division, aimed at sharpening its focus on next-generation therapeutics. This restructuring initiative is designed to streamline operations and accelerate the development and commercialization of advanced modalities including cell and gene therapies, antibody-drug conjugates, and RNA-based treatments as the company positions itself to lead in high-growth, innovation-driven segments of the global biopharmaceutical market.

Key Market Players

• Xencor, Inc.
• Regenxbio & Neurimmune AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• AstraZeneca Plc.
• F. Hoffmann-La Roche Ltd.
• Kyowa Kirin Co., Ltd
• Seattle Genetics, Inc
• ImmunoGen, Inc
• Ono Pharmaceuticals Co, Ltd

Report Scope:

In this report, the Global Next Generation Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Next Generation Biotherapeutics Market, By Therapeutic Area:

o   Oncology

o   Autoimmune/ Inflammatory Diseases

• Next Generation Biotherapeutics Market, By Technology:

o   Antibody-Drug Conjugates

o   Bispecific Antibodies

o   Antibody Fragments

o   Antibody-like Proteins

o   Others

• Next Generation Biotherapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Biotherapeutics Market.

Available Customizations:

Global Next Generation Biotherapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Next Generation Biotherapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]